Translational research in neuroendocrine tumors (NETs): What's new in 2021? - 13/12/22
Doi : 10.1016/j.ando.2022.09.001
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Esquema
| ☆ | This review/synthesis is an adaptation of a talk given during the last Annual Meeting of the French Endocrine Tumor Study Group (GTE: Groupe d’Étude des Tumeurs Endocrines) in Paris in December 2021 (see www.reseau-gte.org%20for%20details/). The speaker was asked to provide a personal selection of the most important advances published in the preceding year on the pathogenesis of NETs and on biomarkers useful for diagnosis, prognosis or therapy selection. |
© 2022
The Author(s). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 83 - N° 6
P. 469-471 - décembre 2022 Regresar al número
Artículo precedente
- Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Cambridge, UK, 7–8 April 2022
- Héléna Mosbah, Baris Akinci, David Araújo-Vilar, Juan Carrion Tudela, Giovanni Ceccarini, Philippe Collas, I. Sadaf Farooqi, Antía Fernández-Pombo, Isabelle Jéru, Fredrik Karpe, Kerstin Krause, Margherita Maffei, Konstanze Miehle, Elif Oral, Naca Perez de Tudela, Xavier Prieur, Justin Rochford, Rebecca Sanders, Ferruccio Santini, David B. Savage, Julia von Schnurbein, Robert Semple, Anna Stears, Ekaterina Sorkina, Marie-Christine Vantyghem, Camille Vatier, Antonio Vidal-Puig, Corinne Vigouroux, Martin Wabitsch
- Sporadic pseudohypoparathyroidism type 1B due to methylation abnormality combined with hypokalemia: A case report and review
- Yajuan Zhang, Xiaojun Song, Wendi Zhang, Tianying Qi, Weixia Sun, Xinli Zhou
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.